Skip to main content
Log in

Treatment-resistant MDD imposes cost burden on US employers

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Amos TB, et al. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database. Journal of Clinical Psychiatry 79: No. 2, 20 Feb 2018. Available from: URL: http://doi.org/10.4088/JCP.17m11725

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Treatment-resistant MDD imposes cost burden on US employers. PharmacoEcon Outcomes News 798, 32 (2018). https://doi.org/10.1007/s40274-018-4779-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4779-4

Navigation